| Kimberly Radtke, APNP | |
|
3400 Ministry Pkwy, Weston, WI 54476-5220 | |
| (715) 393-3000 | |
| Not Available |
| Full Name | Kimberly Radtke |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 3400 Ministry Pkwy, Weston, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407148042 | NPI | - | NPPES |
| 4101 | Other | WI | APNP LIC |
| 128613 | Other | WI | RN LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension St Marys Hospital | Rhinelander, WI | Hospital |
| Howard Young Medical Center | Woodruff, WI | Hospital |
| Ascension Eagle River Hospital | Eagle river, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aspirus Rhinelander And Tomahawk Hospitals And Clinics Inc | 9335059856 | 309 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer.
Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 4 days ago
| Entity Name | Ascension Medical Group-northern Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265507537 PECOS PAC ID: 8426960022 Enrollment ID: O20031103000345 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer.
Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 4 days ago
| Entity Name | Aspirus Rhinelander & Tomahawk Hospitals & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144991340 PECOS PAC ID: 9335059856 Enrollment ID: O20031126000706 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer.
Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 4 days ago
| Entity Name | Howard Young Medical Center Inc Of Woodruff Wisconsin |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184673352 PECOS PAC ID: 4183519606 Enrollment ID: O20040419000970 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer.
Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 4 days ago
| Entity Name | Aspirus Stevens Point Hospital & Clinics, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538112230 PECOS PAC ID: 1850358938 Enrollment ID: O20041210000558 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer.
Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Radtke, APNP 3400 Ministry Pkwy, Weston, WI 54476-5220 Ph: (715) 393-3000 | Kimberly Radtke, APNP 3400 Ministry Pkwy, Weston, WI 54476-5220 Ph: (715) 393-3000 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer.
Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.
› Verified 4 days ago
Gabrielle Marie Weber, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 5703 Memorial Ct, Weston, WI 54476 Phone: 715-204-9808 | |
Tina K Schultz, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-3000 | |
Jessica Engel, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-1220 | |
James E Conner, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-3000 | |
Diane M. Joyce, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3501 Cranberry Blvd, Weston, WI 54476 Phone: 715-393-1000 | |
Kristin D Doede, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6303 Schofield Ave, Weston, WI 54476 Phone: 715-393-4092 Fax: 866-885-5412 | |
Dane Jae Harder, CRNA Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3400 Ministry Pkwy, Weston, WI 54476 Phone: 715-393-2652 |